Paper Details

  1. Home
  2. Paper Details

How do patients feel during the first 72 h after initiating long-acting injectable buprenorphine? An embodied qualitative analysis.

Author: NealeJoanne, ParkinStephen, StrangJohn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Long-acting injectable buprenorphine (LAIB) is a new treatment for opioid use disorder. While typically well-tolerated, some patients experience negative effects. This study explores patients' experiences during the first 72 hours after initiating LAIB treatment to better understand these potential side effects and how they can affect treatment adherence.
Paper Details　
Original Abstract of the Article :
Long-acting injectable buprenorphine (LAIB) is a new treatment for opioid use disorder that is generating positive outcomes. Negative effects are typically mild and transient, but can occasionally be serious, resulting in treatment discontinuation/non-adherence. This paper aims to analyse patients' ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/add.16171

データ提供：米国国立医学図書館（NLM）

Long-Acting Injectable Buprenorphine: A User's Perspective

Long-acting injectable buprenorphine (LAIB) is a new treatment for opioid use disorder, offering a potential pathway towards recovery. This research delves into the patients' experiences during the first 72 hours after initiating LAIB, providing valuable insights into the immediate effects of this medication. Imagine a camel caravan embarking on a long journey, where the travelers must adapt to a new environment and way of life. LAIB is like a map guiding them through the early stages of their journey, providing support and stability as they transition to a new state.

Navigating the Early Stages of LAIB Treatment

This study explores the patients' subjective experiences during the initial phase of LAIB treatment, providing valuable information about the immediate effects of the medication. The authors analyzed patients' accounts of how they felt during the first 72 hours, shedding light on the potential challenges and benefits of this treatment approach. This research is like a diary, documenting the personal journeys of patients as they embark on their recovery journey with LAIB.

Understanding the Patient Experience

This research highlights the importance of understanding the patient experience with LAIB, recognizing both the potential benefits and challenges associated with this treatment. The authors emphasize the need for ongoing support and guidance for patients during the early stages of LAIB treatment, ensuring a smooth and successful transition to this new approach. This research is like a compass, guiding healthcare professionals towards a deeper understanding of the patient experience with LAIB, enabling them to provide tailored support and care.

Dr.Camel's Conclusion

This research provides valuable insights into the patient experience during the initial phase of long-acting injectable buprenorphine (LAIB) treatment. The authors' analysis of patient accounts highlights the importance of understanding the immediate effects of LAIB and providing ongoing support and guidance for patients during this crucial transition phase.

Date :
  1. Date Completed 2023-06-14
  2. Date Revised 2023-06-18
Further Info :

Pubmed ID

36808168

DOI: Digital Object Identifier

10.1111/add.16171

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.